Managing NON-DIAGNOSTIC biopsies in musculoskeletal tumours in a specialist centre: Deciding on the algorithm.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
05 2021
Historique:
received: 03 07 2020
revised: 05 10 2020
accepted: 09 10 2020
pubmed: 21 10 2020
medline: 12 10 2021
entrez: 20 10 2020
Statut: ppublish

Résumé

Core needle biopsy is an effective method of obtaining tissue diagnosis. However, a diagnostic dilemma arises when lesional tissue is non-diagnostic which obviates considering radiological guided re-biopsy (RB) or an open surgical biopsy but the question raised is which serves as a better diagnostic tool. We retrospectively reviewed data from a prospectively collected database of 4516 core needle biopsies performed in our specialist musculoskeletal tumour centre over a 6-year period. Our aim was to evaluate the management of non-diagnostic biopsies (NDB) and establish a safe and accurate diagnostic strategy in the presence of a NDB. Two hundred fifteen (4.8%) NDB cases with complete follow-up were identified. Of these 157 (73%) were treated definitively on the basis of imaging and 58 (27%) had a RB, 48 (83%) of which led to a positive histological diagnosis. The remaining 10 were again non-diagnostic giving a total of 167 patients being treated definitively without a tissue diagnosis. The sensitivity and specificity for multidisciplinary team (MDT) assessment as a diagnostic tool was 0.75 and 0.88 respectively while that for RB was 0.91 and 0.9. Re-biopsy after first non-diagnostic core needle biopsy offers high sensitivity and specificity, especially in the presence of malignancy. In the absence of tissue diagnosis, however, MDT assessment is also highly accurate and a safe strategy in managing this complex group of patients. Diagnostic Level III.

Identifiants

pubmed: 33077295
pii: S0748-7983(20)30844-1
doi: 10.1016/j.ejso.2020.10.011
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1207-1213

Informations de copyright

Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved.

Auteurs

George S Tamvakopoulos (GS)

Department of Orthopaedic Oncology, Royal National Orthopaedic Hospital, Stanmore, UK. Electronic address: gst@doctors.net.uk.

Barry Rose (B)

Department of Orthopaedic Oncology, Royal National Orthopaedic Hospital, Stanmore, UK.

Asif Saifuddin (A)

Department of Radiology, Royal National Orthopaedic Hospital, Stanmore, UK.

John A Skinner (JA)

Department of Orthopaedic Oncology, Royal National Orthopaedic Hospital, Stanmore, UK.

Robin Pollock (R)

Department of Orthopaedic Oncology, Royal National Orthopaedic Hospital, Stanmore, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH